Part 8/11:
Despite China's promising trajectory, the path to becoming a leading innovator is fraught with hurdles. The US has recently introduced legislation, notably the "Biosecure Bill," passed by the House of Representatives in September 2024, which restricts US collaborations with certain Chinese biotech firms involved in drug discovery and manufacturing.